1. Brad Spellberg In: Mandell GL, Bennett JE, Dolin R (eds). Principles of Antiinfective Therapy Principles and Practice of Infectious Diseases. 9th edition. Philadelphia: Churchill Livingstone;
2020.
2. Baran, A, Kwiatkowska A, Potocki L. Antibiotics and Bacterial Resistance—A Short Story of an Endless Arms Race. Int. J. Mol. Sci. 2023; 24, 5777. https://doi.org/ 10.3390/ijms24065777
3. Reygaert WC. An overview of the antimicrobial resistance mechanisms of bacteria. AIMS Microbiology 2018; 4(3): 482–501. DOI: 10.3934/microbiol.
4. Bo L, Sun H, Li DY et al. Combating antimicrobial resistance: the silent war. Front. Pharmacol 2024; 15:1347750.doi:10.3389/fphar.2024.1347750
5. Bradford PA, Castanheira M. Mechanisms of resistance to antibacterial agents in Pfaller MA, Carroll CK (eds) Manual of Clinical Microbiology 13th edition, Washington DC. ASM press,
2023: 1375-1410.
6. Peterson E and Kaur P. Antibiotic Resistance Mechanisms in Bacteria: Relationships Between Resistance Determinants of Antibiotic Producers, Environmental Bacteria, and Clinical Pat-
hogens. Front. Microbiol. 2018; 9:2928. doi: 10.3389/fmicb.2018.02928
7. Canton R, Ruiz-Garbajosa P. Co-resistance: an opportunity for the bacteria and resistance genes. Current opinion in pharmacology 2011; 11:477-485.
8. Munita JM, Arias CA. Mechanisms of Antibiotic Resistance Microbiol Spectr. 2016; 4(2): doi:10.1128/microbiolspec.VMBF-0016-2015.
9. Dominguez S, da Silva GJ, Nielsen KM. Vehicles and pathways for horizontal dissemination in bacteria. Mob Genet Elements. 2012 ; 2(5):211-223.
10. Opal SM, Pop-Vicas Aurora. Molecular Mechanisms of antibiotic resistance in bacteria. In: Mandell GL, Bennett JE, Dolin R (eds). Principles and Practice of Infectious Diseases. 9th edition.
Philadelphia: Churchill Livingstone; 2020.
11. Mora-Ochomogo M, Lohans CT. β-Lactam antibiotic targets and resistance mechanisms: from covalent inhibitors to substrates. RSC Med. Chem 2021; 12: 1623-1639. https://doi.org/ 10.1039/
d1md00200g
12. Sethuvel DPM . Bakthavatchalam YD, Karthik M, Irulappan M, Shrivastava R, Periasamy H, Veeraraghavan B. ß-Lactam Resistance in ESKAPE Pathogens Mediated Through Modifications
in Penicillin-Binding Proteins: An Overview. Infect Dis Ther 2023; 12: 829–841
13. Bush K, Bradford PA. 2020. Epidemiology of β-lactamase-producing pathogens. Clin Microbiol Rev 2020; 33:e00047-19. https://doi.org/10.1128/CMR.00047-19.
14. Uehara, Y. Current Status of Staphylococcal Cassette Chromosome mec (SCCmec). Antibiotics 2022; 11: 86. https:// doi.org/10.3390/antibiotics11010086
15. Lakhundi S, Zhang K, Methicillin-resistant staphylococcus aureus: molecular characterization, evolution, and epidemiology. Clin. Microbiol Rev. 2018; 31:e00020-18. https://doi.org/10.1128/
CMR.00020-18.
16. Jiang JH, Cameron DR, Nethercott C, Sousa MA, Peleg AY. Virulence attributes of successful methicillin-resistant Staphylococcus aureus lineages. Clin Microbiol Rev 2023; 34 (Suppl 1): S3-10.
17. Shore AC, Coleman DC. Staphylococcal casette chromosome mec: Recent advances and new insights. Int J Med Microbiol 2013; 303: 350-359.
18. Otto M. Community-associated MRSA: What makes them special? Int J Med Microb 2013; 303: 324-330.
19. Freire S, FindlayJ, Gruner E, Bruderer V, Nordmann P, Poirel L. Modification of the penicillin-binding-protein 3 as a source of resistance to broad-spectrum cephalosporins in Escherichia coli.
JAC 2024; 79: 930–932.
20. Hernando-Amado S, Blanco P, Alcalde-Rico M, Corona F, Reales-Calderón JA, Sánchez MB, José L. Martínez JL. Multidrug efflux pumps as main players in intrinsic and acquired resistance
to antimicrobials. Drug Resistance Updates 2016; 28: 13-27.
21. Tamma PD, Doi Y, Bonomo RA et al. A Primer on AmpC β-Lactamases: Necessary Knowledge for an Increasingly Multidrug-resistant World Clin Infec Dis 2019; 69(8):1446–55.
22. Livermore DM. ß-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995; 8(4): 557-584.
23. Gür D, Pitt TL, Hall LMC, Akalın HE, Livermore DM. Diversity of klebsiellae with extended-spectrum beta-lactamases at a Turkish University Hospital. J Hosp Infect 1992; 22: 163-166.
24. Castanheira M, Simner PJ, Bradford PA. Extended-spectrum ß-lactamases: an update on their characteristics, epidemiology and detection. 2021; 16 (3):dlab092. doi: 10.1093/jacamr/dlab092.
25. R. Canton R, M. I. Morosini IM, Martin O et al. S. IRT and CMT b-lactamases and inhibitor resistance. Clin Microbiol Infect 2008; 14 (Suppl. 1): 53–62.
26. D’Andrea MM, Arena F, Pallechi L, Rossolini GM. CTX-M-type ß-lactamases: A successful story of antibiotic resistance. Int J Med Microbiol 2013; 303: 305-317.
27. Poirel L, de la Rosa J-MO, Richard A et al. 2019. CTX-M33 is a CTX-M-15 derivative conferring reduced susceptibility to carbapenems. Antimicrob Agents Chemother 63:e01515-19. https://
doi .org/10.1128/AAC.01515-19.
28. Hall LMC, Livermore DM, Gür D, Akova M, Akalın HE. OXA-11, an extended-spectrum variant of OXA-10 (PSE-2) b-lactamase from Pseudomonas aeruginosa. Antimicrob Agents Chemo-
ther 1993; 37:1637-1644.
29. Danel F, Hall LMC, Duke B, Gür D, Livermore DM. OXA-17, a further extended-spectrum variant of OXA-10 ß-lactamase, isolated from Pseudomonas aeruginosa. Antimicrob Agents Che-
mother 1999; 43: 1362-1366.
30. Danel F, Hall LMC, Gür D, Akalın HE, Livermore DM.Transferable production of PER-1 ß-lactamase in Pseudomonas aeruginosa. J Antimicrob Chemother 1995; 35:281-294.
31. Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions.
Clin Microbiol rev 2012; 25: 682-707.
32. Jacoby G, Bush K. ß-lactam resistance in 21st century in: DG White, MN Alekshun, PF McDermott (eds). Frontiers in Antimicrobial Resistance, first ed., Washington D.C., ASM press 2005.
33. Gur D, Korten V, Unal S, Desphande LM, Castanheira M. Increasing carbapenem resistance due to the clonal dissemination of oxacillinase (OXA-23 and OXA-58)-producing Acinetobacter
baumannii: report from the Turkish SENTRY Program sites. J Med Microbiol 2008; 57:1529-1532.
34. Çakar A, Akyön Y, Gür D, ve ark. Investigation of carbapenemases in carbapenem-resistant Escherichia coli and Klebsiella pneumoniae strains isolated in 2014 in Turkey. Mikrobiyol Bul.
2016; 50(1):21-33.
35. Hajo Grundmann, Corinna Glasner, Barbara Albiger, et al. Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenema-
se-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study. The Lancet Infectious Diseases 2017; 17(2): 153–163.
36. Süzük Yıldız S, Şimşek H, Bakkaloğlu Z ve ark. Türkiye’de 2019 Yılı İçinde İzole Edilen Escherichia coli ve Klebsiella pneumoniae İzolatlarında Karbapenemaz Epidemiyolojisi. Mikrobiyol Bul
2021; 55(1):1-16/doi: 10.5578/mb.20124.
37. Altun B, Hazırolan G, Gür D. K. pneumoniae izolatlarının Seftazidim, Meropenem Ve Beta-Laktamaz İnhibitörlerine İn Vitro Duyarlılığı ve Karbapenemaz Enzimlerinin Belirlenmesi (2015-
2022); poster no: 06. 15. Antimikrobik Kemoterapi Günleri, 9-11 mayıs 2024, Marmara Üniversitesi Pendik Eğitim ve Araştırma Hastanesi, İstanbul.
38. Doi Y, Wachino JI, Arakawa Y, Aminoglycoside resistance, The emergence of acquired 16S ribosomal RNA methyltransferases. Infect Dis Clin N Am 2016; (30): 523-37.
39. Miller GH, Sabatelli FJ, and the Aminoglycoside Resistance Study Groups. The Most Frequently Occuring Aminoglycoside Resistance Mechanisms-Combined results of surveys in eight
regions of the world. J Chemother 1995;7(suppl.2): 17-30.
40. Över U, Gür D, Ünal S, Miller GH, Aminoglycoside Resistance Study Group. The changing nature of aminoglycoside resistance mechanisms and prevalence of newly recognized resistance
mechanisms in Turkey. Clin Microbiol Infect 2001; 7:470-478.
41. Hooper DC, Jacoby GA. Mechanisms of drug resistance: quinolone resistance. Ann. N.Y. Acad. Sci. 2015; 1354 : 12-31. doi: 10.1111/nyas.12830.
42. Yang W., Hu, F. Research Updates of Plasmid-Mediated Aminoglycoside Resistance 16S rRNA Methyltransferase. Antibiotics 2022; 11: 906. https://doi.org/ 10.3390/antibiotics11070906
43. Gür D, Hasdemir U, Çakar A, Çavuşoğlu İ, Çelik T, Aksu B; Plazomicin Study Group. Comparative in vitro activity of plazomicin and older aminoglyosides against Enterobacterales isolates;
prevalence of aminoglycoside modifying enzymes and 16S rRNA methyltransferases. Diagn Microbiol Infect Dis. 2020 Aug;97(4):115092. doi: 10.1016/j.diagmicrobio. 2020.115092.
44. Aldred KJ, Kerns RJ, Osheroff N. Mechanism of quinolone action and resistance. Biochemistry 2014; 53: 1565-1574.
45. Kherroubi L, Bacon J, Rahman KM. Navigating fluoroquinolone resistance in Gram-negative bacteria: a comprehensive evaluation. JAC Antimicrob Resist. 2024; 14: 6(4):dlae127. doi:
10.1093/jacamr/dlae127. eCollection 2024 Aug.
46. Ruiz J. Transferable mechanisms of quinolone resistance from 1998 onward. Clin Microbiol Rev 2019; 32(4):e00007-19. doi: 10.1128/CMR.00007-19.
47. Murray BE, Arias CA, Nannini EC. Glycopeptides (Vancomycin and Teicoplanin) and Lipoglycopeptides (Telavancin, Oritavancin, and Dalbavancin). In: Mandell GL, Bennett JE, Dolin R
(eds). Principles and Practice of Infectious Diseases. 9th edition. Philadelphia: Churchill Livingstone, 2020.
48. Debabov D; Zeng D. Hartsell TL et al. Approved Glycopeptide Antibacterial Drugs: Mechanism of Action and Resistance, Cold Spring Harb Perspect Med 2016; 6:a026989. doi: 10.1101/
cshperspect.a026989.
49. Santos-Beneit F, Ordóñez-Robles M, Martin JF. Glycopeptide resistance: Links with inorganic phosphate metabolism and cell envelope stress. Biochemical Pharmacology 2017; 133: 74-85.
50. Xavier BB, Coppens J, De Koster S. et al. Novel vancomycin resistance gene cluster in Enterococcus faecium ST1486, Belgium, June 2021. Euro Surveill. 2021; 26(36):pii=2100767. https://
doi.org/10.2807/1560-7917.ES.2021.26.36.2100767
51. Xu X, Lin D, Yan G, Ye X, et al. vanM, a new glycopeptide resistance gene cluster found in Enterococcus faecium. Antimicrob Agents Chemother 2010; 54: 4643-4647
52. McGuinness WA, Malachowa N, DeLeo FR. Vancomycin Resistance in Staphylococcus aureus Yale Journal of Biology and medicine 2017; 90: 269-281.
53. Cong Y, Yang S, Rao X. Vancomycin resistant Staphylococcus aureus infections: A review of case updating and clinical features. J. Adv. Res.2020; 21: 169-176.
54. Howden BP, Davies JK, Johnson PDR, Stinear TP, Grayson MLG. Reduced susceptibility in Staphylococcus aureus, including vancomycin-intermediate strains: Resistance mechanisms, labo-
ratory detection and clinical implications. Clin Microb Rev 2010; 23: 99-139.
55. Sancak B, Yagci S, Gür D et al. Vancomycin and daptomycin minimum inhibitory concentration distribution and occurrence of heteroresistance among methicillin-resistant Staphylococcus
aureus blood isolates in Turkey. BMC Infectious Diseases 2013; 13: 583-588.
56. Roberts MC, Sutcliffe J. Macrolide, lincosamide, streptogramin, ketolide, and oxazolidinone resistance. In : DG White, MN Alekshun, PF McDermott (eds) Frontiers in Antimicrobial resis-
tance, 1.st ed Washington DC, ASM Press, 2005.
57. Mlynarczyk-Bonikowska, B, Kowalewski, C, Krolak-Ulinska, A, Marusza W. Molecular Mechanisms of Drug Resistance in Staphylococcus aureus. Int. J. Mol. Sci. 2022; 23. 8088. https://doi.
org/ 10.3390/ijms23158088.
58. Amdana NAN, Shahrulzamri NA, Hashima R, Jamil NM. Understanding the evolution of macrolides resistance: A mini review. J Glob Antimicrob Resist 2024; 6:38:368-375. doi: 10.1016/j.
jgar.2024.07.016.
59. Rossolini GM, Mantengoli E, Montagnani F, Pollini S. Epidemiology and clinical relevance of microbial resistance determinants versus anti-Gram-positive agents. Current Opinion in Micro-
biology 2010; 13:582–588
60. Wang Y, Lv Y, Cai J et al. A novel gene, optrA, that confers transferable resistance to oxazolidinones and phenicols and its presence in Enterococcus faecalis and Enterococcus faecium of human
and animal origin. J Antimicrob Chemother 2015; 70: 2182–2190 doi:10.1093/jac/dkv116.
61. Sharma J, Sharma D, Singh A, Kumari S. Colistin resistance and management of drug resistant infections. Can J Infect Dis Med Microbiol 2022; Published onlin 2e022 Dec
10. doi: 10.1155/2022/4315030.
62. Mondal AH, Khare K, Saxena P, Debnath P, Mukhopadhyay K, Yadav D. A Review on colistin resistance: An antibiotic of last resort microorganisms. 2024; 12(4): 772.
63. Andrade FF, Silva D, Rodriguez A, Pina-Vaz C. Colistin update on its mechanism of action and resistance, present and future challenges. Microorganisms 2020; 8: 1716; doi:10.3390/micro-
organisms8111716
64. Liu HJ, Liu YY, Shen YB et al. Plasmid-mediated colistin-resistance genes: mcr Trends in Microbiology, April 2024, Vol. 32, No. 4 https://doi.org/10.1016/j.tim.2023.10.006
65. Jiang Y, Peng K, Wang Q, Wang M, Li R, Wan Z. Novel Trimethoprim Resistance Gene dfrA49 Identified in Riemerella anatipestifer from China. Microbiology spectrum 2023; 11(2):
e0474722. doi: 10.1128/spectrum.04747-22.
66. Heidary M, Khosravi AD, Khoshnood S. Daptomycin. J Antimicrob Chemother 2018; 73: 1–11 doi:10.1093/jac/dkx349
67. Palmer KL, Daniel A, Hardy C,Silverman J,Michael S. Gilmore MS. Genetic Basis for Daptomycin Resistance in Enterococci. Antimicrob Agents Chemother 2011, 55: 3345-3356.
68. Thaker M, Spanogiannopoulos P. Wright GD. The tetracycline resistome. Cell. Mol. Life Sci. 2010; 67:419–431
69. Emergence of plasmid-mediated high-level tigecycline resistance genes in animals and humans He t, Wang R, Dejun L, Walsh TR, Nature Microbiology 2019; 4: 1450-1456.
70. Mattioni Marchetti V, Hrabak J, Bitar I . Fosfomycin resistance mechanisms in Enterobacterales: an increasing threat. Front. Cell. Infect. Microbiol. 2023; 13:1178547. doi: 10.3389/
fcimb.2023.1178547
71. Falagas ME, Athanasaki F, Voulgaris GL, Triarides NA, Vardakas ZK. Resistance to fosfomycin: Mechanisms, Frequency and Clinical Consequences Int J AntimicrobAgents 2019; 53; 22–28
72. Zurfluh K, Treier A, Schmitt K, Stephan R. Mobile fosfomycin resistance genes in Enterobacteriaceae— An increasing threat. MicrobiologyOpen. 2020;9:e1135https://doi.org/10.1002/
mbo3.1135.
73. Nigiz Ş, Hazırolan G, Köseoglu Eser Ö, Gür D. First detection of Klebsiella pneumoniae isolate co-harboring fosfomycin resistance gene fosA3 and bla ctx-m among gram negative urine
isolates in a Turkish Hospital. Microb Drug resist 2022; 28(3): 317-321. doi: 10.1089/mdr.2021.0114.
74. Ito Y, Hashimoto Y, Suzuki M et al. The emergence of metronidazole-resistant Prevotella bivia Harboring nimK gene in Japan. Microbiol Spectr 2024 Aug 20:e0056224. doi: 10.1128/spect-
rum.00562-24. Online ahead of print.
75. Huang Z, Zhu Y, Xinhang L, Xinhang L, Yao Z, Ruiguang G. The mechanisms of metronidazole resistance of Helicobacter pylori: A transcriptomic and biochemical study. Microb Pathog 2023;
183: 106303. Doi: 10.1016/j.micpath.2023.106303.